Navigation Links
China Medicine to Showcase 'Bethin' Weight Loss Product at 2008 Natural Products Expo East Trade Show
Date:10/13/2008

GUANGZHOU, China, Oct. 13 /Xinhua-PRNewswire/ -- China Medicine Corporation (OTC Bulletin Board: CHME; "China Medicine" or "the Company"), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and dietary supplements, medical devices, and medical formulations in the People's Republic of China ("PRC"), through its wholly-owned U.S subsidiary, Konzern U.S Holding Corporation, announced today that it will participate in the 2008 Natural Products Expo East tradeshow, where it will showcase its new weight loss product called "Bethin." The tradeshow will be held Oct. 15th to Oct. 18th at the Boston Convention & Exhibition Center in Massachusetts. Over 25,000 natural, organic, and health products industry members will participate in this event.

China Medicine's proprietary weight loss product, Bethin, is a food supplement that is designed to promote and adjust fat metabolism, reduce the storage of fat in the body, and prolong endurance during physical exercise. Bethin's active ingredients include L-Carnitine, a special amino acid manufactured by the human body that is essential for the production of energy, and Hydroxycitric acid (HCA), an extract from the fruit of the Garcinia cambogia plant. The Company has filed and obtained all the necessary documentation to launch the new product in the United States.

"We are looking forward to taking part in the upcoming Natural Products Expo East tradeshow in Boston," said Mr. Senshan Yang, Chairman and CEO of China Medicine. "We anticipate that the introduction of Bethin, our first product sold in U. S. market, will increase our visibility, highlight the benefits of our new product, and allow us to gain a foothold in the international market."

The Company will be exhibiting its product in booth #240. For more information on the tradeshow, please click http://www.expoeast.com .

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company which discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements. The Company distributes the products to wholesale distributors in 28 provinces, more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feed. For more information visit the Company's website at http://www.chinamedicinecorp.com .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.

For further information, please contact:

China Medicine Corp

Ms. Huizhen Yu

CFO

Tel: +86-20-8739-1718

Email: konzern08@163.com

Mr. Crocker Coulson

President

CCG InvestorRelations Inc.

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
2. China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
3. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
4. Covance Decides to Pursue Its Original Preclinical Strategy in China
5. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
6. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
7. tootoo.com: Chinas Farmers Welcome the New Trend of Organic Farming
8. China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification
9. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
10. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
11. China Biopharma Effects 1 for 100 Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth management ... The Future of San Diego Life Science event at the Estancia La Jolla Resort ... the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the second quarter of 2016. The cash ... about July 29, 2016 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman Prizes. ... are given in two categories, one for experiment and the other for theory ...
(Date:5/20/2016)... ... 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell ... treat the disease. Surviving Mesothelioma has just posted an article on the new study. ... based their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):